Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy.
Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy.
Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.
In chronic lymphocytic leukemia (CLL), stabilizing mutations of NOTCH1, affecting up to 10-15% of cases, have been associated to poor prognosis, disease progression and refractoriness to chemotherapy. NOTCH1 mutations are significantly overrepresented in trisomy 12 CLL, a disease subset frequently expressing CD49d, the α4 chain of the very-late-activation-4 integrin, a well-known key regulator of microenviromental interactions, and negative prognosticator in CLL. In the present study, by analysing a wide cohort of 1180 CLL, we observed a very strong association between the presence of NOTCH1 mutations and the expression of CD49d (P<0.0001), occurring also outside the trisomy 12 CLL subset. Using both the MEC-1 CLL-like cells stably transfected with the NOTCH1 intracellular domain and primary CLL cells bearing a mutated or wild-type NOTCH1 gene configuration, we provide evidence that triggering of the NOTCH1 pathway resulted in a positive CD49d expression regulation, which was driven by a NOTCH1-dependent activation of nuclear factot-κB (NF-κB). Consistently, pharmacological inhibition of the NOTCH1 and/or of the NF-κB pathways resulted in impaired NF-κB nuclear translocation with consequent down-modulation of CD49d expression. Altogether, our data link for the first time NOTCH1 mutations to CD49d expression regulation through the involvement of the NF-κB pathway in CLL.
在慢性淋巴细胞白血病(CLL)中,稳定的 NOTCH1 突变影响了多达 10-15%的病例,与预后不良、疾病进展和对化疗的耐药性有关。NOTCH1 突变在三体 12 CLL 中显著过度表达,这是一种经常表达 CD49d 的疾病亚群,CD49d 是非常晚期激活 4 整合素的 α4 链,是微环境相互作用的已知关键调节剂,也是 CLL 的不良预后标志物。在本研究中,通过分析广泛的 1180 例 CLL 队列,我们观察到 NOTCH1 突变与 CD49d 的表达之间存在非常强的关联(P<0.0001),即使在三体 12 CLL 亚群之外也存在这种关联。通过使用稳定转染 NOTCH1 细胞内结构域的 MEC-1 CLL 样细胞和携带突变或野生型 NOTCH1 基因构型的原发性 CLL 细胞,我们提供了证据表明 NOTCH1 途径的触发导致了 CD49d 的阳性表达调节,这是由 NOTCH1 依赖性核因子-κB(NF-κB)激活驱动的。一致地,NOTCH1 和/或 NF-κB 途径的药理学抑制导致 NF-κB 核易位受损,从而导致 CD49d 表达下调。总之,我们的数据首次将 NOTCH1 突变与 CLL 中通过 NF-κB 途径的 CD49d 表达调节联系起来。